CoDon

CoDon EBIT per Employee

The EBIT per Employee of CoDon (CNW.F) as of Nov 5, 2026 is -62,589.55 EUR. In the previous year, EBIT per Employee was -81,783.58 EUR — a change of -23.47% (higher).

EBIT per Employee

-62,589.55EUR

YoY

-23.47%

Last updated:

EBIT per Employee of CoDon is 2021 -62,589.55 EUR. EBIT per Employee of CoDon was 2020 -81,783.58 EUR. It decreases by -23.47% higher compared to the previous year.

The CoDon EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2014
-16,591.66 EUR
Jan 1, 2015
-21,335.20 EUR
Jan 1, 2016
-27,222.33 EUR
Jan 1, 2017
-52,068.04 EUR
Jan 1, 2018
-63,888.06 EUR
Jan 1, 2019
-70,500.00 EUR
Jan 1, 2020
-81,783.58 EUR
Jan 1, 2021
-62,589.55 EUR
The CoDon EBIT per Employee history
YEAREBIT per EmployeeYoY
-62,589.55EUR-23.47%
-81,783.58EUR+16.01%
-70,500.00EUR+10.35%
-63,888.06EUR+22.70%
-52,068.04EUR+91.27%
-27,222.33EUR+27.59%
-21,335.20EUR+28.59%
-16,591.66EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CoDon Stock analysis

What does CoDon do? co.don AG develops and sells cell-based biological drugs for regenerative medicine, focusing on orthopedic and neurosurgical applications. Its key products include co don chondrotransplant for knee cartilage defects, co don chondrosphere for three-dimensional cartilage cultivation, co don chondrotransplant DISC for intervertebral disc regeneration, and co don osteotransplant DENT for dental bone cell transplants. The company targets medical professionals and clinics in Germany and other European countries, with its products treating conditions like focal cartilage defects, lumbar disc herniation, non-union fractures, and dental disorders. co.don AG generates revenue through direct sales of these specialized biological drugs to healthcare providers. The firm operates with a product portfolio centered on autologous cell therapies, where patient-derived cells are cultivated for personalized treatments. co don chondrotransplant DISC addresses spinal disc issues, while co don osteotransplant DENT serves dental applications, expanding the company's reach beyond orthopedics. All products are manufactured in-house and sold directly to medical institutions across Europe, with no mention of third-party distribution or additional revenue streams in the business description. co.don AG's revenue model relies on the commercialization of its four primary product lines, each addressing specific medical conditions. The company's focus on regenerative treatments for cartilage, disc, and dental applications ensures a steady demand from clinics specializing in these areas. Sales are conducted within Germany and other European markets, with no indication of global expansion or additional segments beyond the described product uses. CoDon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CoDon stock

EBIT per Employee of CoDon is -62,589.55 EUR in 2021.

EBIT per Employee of CoDon changed from -81,783.58 EUR to -62,589.55 EUR, representing a -23.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee CoDon since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's CoDon historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — CoDon

All Key Metrics — CoDon